Results 101 to 110 of about 126,024 (329)

Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF [PDF]

, 2010
Background Cumulative light exposure is significantly associated with progression of age-related macular degeneration (AMD). Inhibition of vascular endothelial growth factor is the main target of current antiangiogenic treatment strategies in AMD ...
Alge, C. S., Hirneiß, Christoph, Kampik, Anselm, Kernt, Marcus, Liegl, R. G., Neubauer, A. S., Ulbig, Michael W., Wolf, Armin   +7 more
core   +3 more sources

GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis

Cell Death and Disease, 2020
Increasing evidence supports that ferroptosis plays an important role in tumor growth inhibition. Sorafenib, originally identified as an inhibitor of multiple oncogenic kinases, has been shown to induce ferroptosis in hepatocellular carcinoma (HCC ...
Qiujie Wang, Cheng Bin, Q. Xue, Qing-zhu Gao, A. Huang, Kai Wang, N. Tang   +6 more
semanticscholar   +1 more source

PDIA3 Inhibition Facilitates Sensitivity of IKE‐Induced Ferroptosis via STAT3/LCN2 Axis to Improve Glioblastoma Therapy

Advanced Science, EarlyView.
In this manuscript, protein disulfide isomerase A3 (PDIA3) is identified as a key factor mediating the susceptibility of ferroptosis in GBM. Inhibition of PDIA3 enhances IKE or cystine starvation‐induced ferroptosis in GBM cells by resulting in the accumulation of lipid peroxidation and a reduction in GSH level.
Jie Zhang, Wei Wang, Xin Liu, Peifen Lu, Xinjing Liu, Qiucheng Nie, Siyuan Xin, Hong Li, Donglin Yu, Xinyue Zhang, Kailong Li, Xiaomin Han, Shuping Zhang, Wei Chong, Lili Sun, Wei Li, Tao Xin, Jin Jiao, Qiang Ma, Yiju Wei   +19 more
wiley   +1 more source

Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031

Journal of Clinical Oncology, 2022
PURPOSE High allelic ratio (HAR) FLT3/ITD (AR > 0.4) mutations confer poor prognosis in pediatric acute myeloid leukemia (AML). COG AAML1031 studied the feasibility and efficacy of adding sorafenib, a multikinase tyrosine kinase inhibitor to standard ...
J. Pollard, T. Alonzo, R. Gerbing, P. Brown, E. Fox, John Choi, B. Fisher, B. Hirsch, S. Kahwash, K. Getz, J. Levine, L. Brodersen, M. Loken, S. Raimondi, Katherine Tarlock, A. Wood, L. Sung, E. Kolb, A. Gamis, S. Meshinchi, R. Aplenc   +20 more
semanticscholar   +1 more source

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma

Pharmaceuticals, 2021
Hepatocellular carcinoma (HCC) recurrence after liver transplantation occurs in approximately 20% of patients. Most of these patients use immunosuppressant drugs.
Koen G. A. M. Hussaarts, Leni van Doorn, Sander Bins, Dave Sprengers, Peter de Bruijn, Roelof W. F. van Leeuwen, Stijn L. W. Koolen, Teun van Gelder, Ron H. J. Mathijssen   +8 more
doaj   +1 more source

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen, Rui Li, Yong She, Xuefei Liu, Yuanyang Huang, Yongling Ji, Keying Chen, Zhengbo Song, Runzhe Chen, Xuan Li, Qi Zhao, Qixun Chen, Ming Chen   +12 more
wiley   +1 more source

Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. [PDF]

PLoS ONE, 2016
Treatment outcomes of sorafenib therapy may greatly vary depending not only on tumor spread but also on past clinical processes prior to sorafenib therapy and timing of sorafenib administration in the past clinical course of hepatocellular carcinoma (HCC)
Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Masanori Inoue, Toru Wakamatsu, Akinobu Tawada, Osamu Yokosuka   +7 more
doaj   +1 more source

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

iScience, 2023
Summary: Drug resistance prominently hampers the effects of systemic therapy of sorafenib to hepatocellular carcinoma (HCC). Epigenetics have critical regulatory roles in drug resistance.
Shanshan Wang, Xin You, Xiaoshu Liu, Fengwei Zhang, Hongjuan Zhou, Xuechai Shang, Long Cai   +6 more
doaj   +1 more source

Halorotetin B, A Novel Terpenoid Compound Derived from Marine Ascidian, Suppresses Tumor Growth by Targeting the Cell Cycle Regulator UBE2C

Advanced Science, EarlyView.
Halorotetin B, a novel small‐molecule terpenoid identified from an edible marine ascidian, exhibits strong anti‐tumor activity both in vitro and in vivo through direct targeting UBE2C to induce tumor cell cycle arrest and then lead tumor cell senescence. As a newly discovered UBE2C inhibitor, Halorotetin B can serve as a novel potential cell senescence
Shanhao Han, Jianhui Li, Yuting Zhu, Penghui Liu, Yaoyao Zheng, Muchun He, Bo Dong   +6 more
wiley   +1 more source

Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma [PDF]

, 2017
PURPOSE: To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial.
Bruix Tudó, Jordi, Carrilho, Flair José, Evans, T.R. Jeffry, Jensen, Markus, Kang, Yoon-Koo, Leberre, Marie-Aude, Llovet i Bayer, Josep Maria, Meinhardt, Gerold, Qin, Shukui, Rosmorduc, Olivier, Ross, Paul J., Santoro, Armando, Thuluvath, Paul J., Zhu, Andrew X.   +13 more
core   +1 more source